About: Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention
Creator	Meanwell, Nicholas Yamanaka, Gregory Yeung, Kap-Sun
source	Medline; PMC
abstract	A novel human coronavirus (CoV) has been identified as the etiological agent that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. The spike (S) protein of this virus is a type I surface glycoprotein that mediates binding of the virus to the host receptor and the subsequent fusion between the viral and host membranes. Because of its critical role in viral entry, the S protein is an important target for the development of anti‐SARS CoV therapeutics and prophylactics. This article reviews the structure and function of the SARS CoV S protein in the context of its role in virus entry. Topics that are discussed include: the interaction between the S1 domain of the SARS spike protein and the cellular receptor, angiotensin converting enzyme 2 (ACE2), and the structural features of the ectodomain of ACE2; the antigenic determinants presented by the S protein and the nature of neutralizing monoclonal antibodies that are elicited in vivo; the structure of the 4,3‐hydrophobic heptad repeats HR1 and HR2 of the S2 domain and their interaction to form a six‐helical bundle during the final stages of fusion. Opportunities for the design and development of anti‐SARS agents based on the inhibition of receptor binding, the therapeutic uses of S‐directed monoclonal antibodies and inhibitors of HR1–HR2 complex formation are presented. © 2006 Wiley Periodicals, Inc. Med Res Rev, 26, No. 4, 414–433, 2006
has issue date	2006-03-06(xsd:dateTime)
bibo:doi	10.1002/med.20055
bibo:pmid	16521129
has license	no-cc
sha1sum (hex)	df650c9c61a64da3a4182d9f9a65800eaf5b1d22
schema:url	https://doi.org/10.1002/med.20055
resource representing a document's title	Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention
has PubMed Central identifier	PMC7168515
has PubMed identifier	16521129
schema:publication	Med Res Rev
resource representing a document's body	covid:df650c9c61a64da3a4182d9f9a65800eaf5b1d22#body_text
is schema:about of	named entity 'virus' named entity 'angiotensin' named entity 'HR2' named entity 'complex formation' named entity 'ectodomain' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software